- Home
- NTIP vs LITS Comparison
NTIP vs LITS Comparison
Compare NTIP & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | LITS |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3M | 36.3M |
| IPO Year | 2013 | 2003 |
Fundamental Metrics
Financial Performance| Metric | NTIP | LITS |
|---|---|---|
| Price | $1.56 | $1.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.7K | ★ 748.4K |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 15.38 | 13.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.00 | N/A |
| 52 Week Low | $1.24 | $0.69 |
| 52 Week High | $1.75 | $2.26 |
Technical Indicators
Market Signals| Indicator | NTIP | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 47.33 |
| Support Level | $1.41 | $1.12 |
| Resistance Level | $1.65 | $1.25 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 64.29 | 16.13 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.